QR-Code

The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-addicted non-small cell lung cancer: A systematic review and sensitivity-analysis

Background: In untreated ALK-positive non-small cell lung cancer no randomized controlled trials (RCTs) are available directly comparing next-generation ALK-inhibitors. We conducted a sensitivity analysis using the likelihood of being helped or harmed (LHH). Methods: Phase III trials comparing ALK-i...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Luca Mastrantoni, Giulia Giordano, Emanuele Vita, Guido Horn, Jacopo Russo, Armando Orlandi, Gennaro Daniele, Diana Giannarelli, Giampaolo Tortora, Emilio Bria
Format: Artigo
Sprache:Inglês
Veröffentlicht: Elsevier 2024-01-01
Schriftenreihe:Cancer Treatment and Research Communications
Schlagworte:
ALK-inhibitors
Alectinib
Lorlatinib
Brigatinib
Ensartinib
LHH
Online-Zugang:http://www.sciencedirect.com/science/article/pii/S2468294224000546
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge